JP2005532789A5 - - Google Patents

Download PDF

Info

Publication number
JP2005532789A5
JP2005532789A5 JP2003576457A JP2003576457A JP2005532789A5 JP 2005532789 A5 JP2005532789 A5 JP 2005532789A5 JP 2003576457 A JP2003576457 A JP 2003576457A JP 2003576457 A JP2003576457 A JP 2003576457A JP 2005532789 A5 JP2005532789 A5 JP 2005532789A5
Authority
JP
Japan
Prior art keywords
protein
seq
amino acid
immunogenic composition
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003576457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005532789A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/007895 external-priority patent/WO2003078453A1/en
Publication of JP2005532789A publication Critical patent/JP2005532789A/ja
Publication of JP2005532789A5 publication Critical patent/JP2005532789A5/ja
Pending legal-status Critical Current

Links

JP2003576457A 2002-03-15 2003-03-13 減少した酵素活性を有する型別不能なインフルエンザ菌(Haemophilusinfluenza)のP4タンパク質の変異体 Pending JP2005532789A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36468802P 2002-03-15 2002-03-15
PCT/US2003/007895 WO2003078453A1 (en) 2002-03-15 2003-03-13 Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity

Publications (2)

Publication Number Publication Date
JP2005532789A JP2005532789A (ja) 2005-11-04
JP2005532789A5 true JP2005532789A5 (enExample) 2008-05-08

Family

ID=28041949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003576457A Pending JP2005532789A (ja) 2002-03-15 2003-03-13 減少した酵素活性を有する型別不能なインフルエンザ菌(Haemophilusinfluenza)のP4タンパク質の変異体

Country Status (12)

Country Link
US (2) US7615229B2 (enExample)
EP (1) EP1490395A4 (enExample)
JP (1) JP2005532789A (enExample)
KR (1) KR100981471B1 (enExample)
CN (1) CN100593544C (enExample)
AU (1) AU2003218162B2 (enExample)
BR (1) BR0308441A (enExample)
CA (1) CA2479118A1 (enExample)
IL (1) IL163988A0 (enExample)
MX (1) MXPA04008890A (enExample)
NZ (1) NZ535754A (enExample)
WO (1) WO2003078453A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012203017B2 (en) * 2003-12-23 2014-10-09 Nationwide Children's Hospital, Inc. Haemophilus Influenzae Type IV Pili
ATE557033T1 (de) * 2003-12-23 2012-05-15 Nationwide Children S Hospital Inc Pili von haemophilus influenzae typ iv
EP2425856A1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
KR101359953B1 (ko) * 2005-06-27 2014-02-21 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
JP4996934B2 (ja) * 2007-02-05 2012-08-08 独立行政法人農業・食品産業技術総合研究機構 組換え型リゾチームの製造法
JP2014516028A (ja) * 2011-05-11 2014-07-07 リースベック ヘルスケア スウェーデン アクティエボラーグ ラミニン及びビトロネクチン結合特性を有するタンパク質f−新規インフルエンザ菌付着因子
WO2020081548A1 (en) * 2018-10-15 2020-04-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Vaccine polypeptide compositions and methods
WO2022056195A1 (en) * 2020-09-10 2022-03-17 The Rochester General Hospital Haemophilus infuluenzae vaccine and methods of use

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US518540A (en) * 1894-04-17 Electric-railway conduit
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4599197A (en) 1982-12-22 1986-07-08 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4518526A (en) 1982-12-22 1985-05-21 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4542104A (en) 1983-04-06 1985-09-17 The Board Of Trustees Of The Leland Stanford Jr. Univ. Phycobiliprotein fluorescent conjugates
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US4734362A (en) 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
DK0606921T3 (da) 1989-03-09 2000-09-04 American Cyanamid Co Fremgangsmåde til isolering af Haemophilus influenzae protein E
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5185440A (en) 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
EP1645635A3 (en) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replication defective recombinant retroviruses expressing a palliative
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5272257A (en) 1990-05-21 1993-12-21 Coulter Corporation Method of preferential labelling of a phycobiliprotein with an amine-reactive dye for use in a multiple color assay and product for such use
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
DK0648271T3 (da) 1991-08-20 2003-07-21 Us Gov Health & Human Serv Adenovirusmedieret overførsel af gener til mave-/tarmkanal
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1993025234A1 (en) 1992-06-08 1993-12-23 The Regents Of The University Of California Methods and compositions for targeting specific tissue
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
CA2145641C (en) 1992-12-03 2008-05-27 Richard J. Gregory Pseudo-adenovirus vectors
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
DE69434469T2 (de) 1993-01-26 2006-06-14 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル. グラハム,フランク 遺伝子治療のためのアデノウイルスベクター
EP0716148B1 (en) 1993-09-15 2004-01-02 Chiron Corporation Recombinant alphavirus vectors
CN1263864C (zh) 1993-10-25 2006-07-12 坎吉公司 重组腺病毒载体及其使用方法
GB9406498D0 (en) 1994-03-31 1994-05-25 Smithkline Beecham Biolog Novel compounds
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5698202A (en) 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
US6168918B1 (en) 1996-01-31 2001-01-02 American Home Products Corp. Method of detecting foreign DNA integrated in eukaryotic chromosomes
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
WO1998010088A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
WO1999021591A1 (en) 1997-10-28 1999-05-06 American Home Products Corporation Compositions and methods for delivery of genetic material
IL138306A0 (en) 1998-03-13 2001-10-31 American Home Prod Polynucleotide composition, method of preparation and use thereof
MXPA01003228A (es) 1998-09-30 2003-06-24 American Cyanamid Co Holotoxina de colera mutante como un coadyuvante.
AU768729B2 (en) 1998-11-05 2004-01-08 Trustees Of The University Of Pennsylvania, The Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
WO2000055335A1 (en) 1999-03-16 2000-09-21 Dana-Farber Cancer Institute, Inc. Pseudotyped lentiviral vectors and uses thereof
JP2004514407A (ja) 2000-04-28 2004-05-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 異種キャプシド中にシュードタイピングされたaav5キャプシドおよびaav5ベクターを含む組換えaavベクター

Similar Documents

Publication Publication Date Title
JP3253327B2 (ja) 髄膜炎菌外層膜蛋白質をコードするヌクレオチド配列を有するポリヌクレオチドおよびワクチン組成物
JP4767540B2 (ja) 髄膜炎菌タンパク質nmb1870の複数の改変体
CN102639558B (zh) 表达系统
JP4144813B2 (ja) Crm蛋白質およびジフテリアトキシンを産生させるための新規なプラスミド
AU2007206114B2 (en) A novel surface exposed Haemophilus influenzae protein (protein E; pE)
JPH11502415A (ja) モラクセラ属(Moraxella)の高分子量主要外膜タンパク
KR100834989B1 (ko) 막 합성 및 막 운반 관련 단백질을 코딩하는코리네박테리움 글루타미쿰 유전자
KR102779223B1 (ko) 변형된 수막구균 fhbp 폴리펩티드
JP2012010706A (ja) 発現系
JP2002512778A (ja) ポリエピトープキャリアタンパク質
JP2006521782A5 (enExample)
JP2010268801A (ja) 髄膜炎菌付着因子
JP2005517380A5 (enExample)
CN110845587B (zh) 一种定点突变的载体蛋白及其在制备疫苗中的用途
JP2005532789A5 (enExample)
US6197929B1 (en) Carrier protein having an adjuvant effect, immunogenic complex containing it, process for their preparation, nucleotide sequence and vaccine
JP5568017B2 (ja) 組換え鶏伝染性コリーザワクチン及びその製造方法
CN1653084A (zh) 酶活性减少的非典型流感嗜血杆菌的p4蛋白突变体
MXPA06000264A (es) Expresion recombinante de cisteina proteasa de streptococcus pyogenes y composiciones inmunogenicas de las mismas.
JP2656098B2 (ja) 可溶性両親媒性タンパク質ならびにその製造および精製法
US6432669B1 (en) Protective recombinant Haemophilus influenzae high molecular weight proteins
WO2004069163A2 (en) Cross-protective epitopes of moraxella catarrhalis and use thereof
JP2002112797A (ja) 組み換え型b型肝炎ウイルス表面抗原の調製方法及び抗原
AU2001256032A1 (en) Co-expression of recombinant proteins
EP1305436A2 (en) Co-expression of recombinant proteins